This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David R. Nalin, MD
Merck Research Laboratories West Point, Pa

JAMA. 1996;276(6):450.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Several points raised by Dr Krause merit clarification. First, Merck was granted a US license for Vaqta (hepatitis A vaccine, inactivated), its hepatitis A vaccine, on March 29,1996; Vaqta went on the market in May 1996. The compositions of Vaqta and Havrix differ (Table). Whether these compositional differences will translate into better safety and tolerability is a scientific question that can only be answered by comparative trials. These trials for rare postvaccination adverse events will, by definition, require adverseexperience report surveillance of large populations of vaccinees that should be accruable over 1 or 2 years. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?